Vanda Pharmaceuticals Inc.

Report azionario NasdaqGM:VNDA

Capitalizzazione di mercato: US$372.2m

Vanda Pharmaceuticals Crescita futura

Criteri Future verificati 2/6

Si prevede che Vanda Pharmaceuticals aumenterà gli utili e i ricavi rispettivamente del 62.6% e 20.4% all'anno, mentre si prevede che l'EPS crescerà del 64.9% all'anno.

Informazioni chiave

62.6%

Tasso di crescita degli utili

64.92%

Tasso di crescita dell'EPS

Biotechs crescita degli utili25.2%
Tasso di crescita dei ricavi20.4%
Rendimento futuro del capitale proprion/a
Copertura analitica

Low

Ultimo aggiornamento11 May 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Aggiornamento della narrazione • May 17

VNDA: Psychiatry Franchise And New Launches Will Drive Earnings Repricing

Analysts have adjusted the fair value estimate for Vanda Pharmaceuticals to $14.90 from $12.67, reflecting updated expectations for profitability, P/E assumptions, and the potential contribution from BYSANTI and other near-commercial assets highlighted in recent research. Analyst Commentary Recent Street research on Vanda Pharmaceuticals presents a mixed picture, with some analysts emphasizing upside from newly approved and near-commercial assets, while others are trimming targets as expectations and assumptions are recalibrated.
Seeking Alpha • May 13

Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss

Summary Vanda Pharmaceuticals is rated a buy, supported by new drug approvals, a diversified clinical pipeline, and strong top-line growth potential. VNDA's near-zero debt and undervalued price/book ratio offer balance sheet strength and significant upside, with Wall St. forecasting considerable price appreciation as of Tuesday's data. Earnings and cash flow trends remain weak, with persistent operating losses, high R&D costs, and no profitability expected until at least 2030. Technical analysis signals a neutral trend, but recent drug launches and upgraded revenue guidance provide a potential growth catalyst. The risk of cash burn was highlighted as well, with about 1.6 years of cash runway expected at current burn rates unless it improves soon. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Apr 28

VNDA: Psychiatry Franchise And Nereus Data Will Shape Balanced Future Prospects

Analysts have raised their average price target on Vanda Pharmaceuticals by $3, from $14 to $17, citing updated revenue models after BYSANTI's approval, expectations for growth in the psychiatry franchise, and potential upside from additional commercial and near-commercial assets. Analyst Commentary Recent research has highlighted a more constructive tone around Vanda Pharmaceuticals, with multiple firms publishing views that anchor on BYSANTI, the broader psychiatry franchise, and the company’s commercial portfolio.
Aggiornamento della narrazione • Apr 14

VNDA: Psychiatry Franchise And Nereus Opportunity Will Shape Balanced Future Upside

Analysts have raised their average price target for Vanda Pharmaceuticals to reflect updated expectations around the recently approved BYSANTI, ongoing prescriptions for Fanapt, and potential upside from Nereus in GLP-1 related vomiting, with current targets from recent research ranging from $17 to $24. Analyst Commentary Recent research has generally been constructive on Vanda Pharmaceuticals, with several firms assigning Buy ratings alongside price targets in the mid to high teens and low twenties.
Aggiornamento della narrazione • Mar 31

VNDA: Psychiatry Franchise And GLP 1 Vomiting Opportunity Will Shape 2026 Outlook

Analysts have raised their fair value estimate for Vanda Pharmaceuticals to $24 from $22, reflecting updated models that incorporate the FDA approval of Bysanti, higher expectations for the psychiatry franchise, and emerging opportunities such as Nereus in GLP-1 related vomiting. Analyst Commentary Bullish analysts are leaning into Vanda's updated story around Bysanti, Fanapt, and newer assets, with several raising fair value assumptions and highlighting a broader psychiatry and gastrointestinal opportunity set.
Aggiornamento della narrazione • Mar 16

VNDA: Psychiatry Reliance Will Limit Upside Despite Recent Drug Approvals

Analysts have raised their average price targets for Vanda Pharmaceuticals into the mid to high teens in dollar terms, citing the recent FDA approval of Bysanti, updated revenue models for the psychiatry franchise, and potential upside from the Nereus program as key reasons for the change. Analyst Commentary Recent Street research around Vanda Pharmaceuticals has centered on the implications of Bysanti's FDA approval, the outlook for the psychiatry franchise, and the potential contribution of pipeline assets such as Nereus and tasimelteon.
Aggiornamento della narrazione • Mar 02

VNDA: Psychiatry Concentration Risk Will Drive A Cautious Forward Outlook

Analysts have lifted their average price target for Vanda Pharmaceuticals to a higher range of $17 to $24, citing updated revenue models that now include expected BYSANTI contributions and revised assumptions for its psychiatry franchise. Analyst Commentary Recent research has centered on the impact of BYSANTI and the broader psychiatry franchise on Vanda Pharmaceuticals, with updated revenue models now reflecting expected BYSANTI contributions and revised assumptions around prescription trends.
Aggiornamento della narrazione • Feb 16

VNDA: Jet Lag Setback Will Keep Focus On 2026 Earnings Outlook

Analysts kept their $22 price target for Vanda Pharmaceuticals unchanged, citing recent FDA feedback on tasimelteon for jet lag as a limited setback that was already excluded from their valuation assumptions. Analyst Commentary Bullish analysts frame the recent FDA feedback on tasimelteon for jet lag as a contained issue.
Aggiornamento della narrazione • Feb 02

VNDA: Jet Lag Setback Will Keep Focus On Imsidolimab BLA Milestone

Analysts have lifted their fair value estimate for Vanda Pharmaceuticals to $22 from $20, citing Street research that views the recent FDA decision on tasimelteon for jet lag as a limited setback that was not factored into prior valuation work. Analyst Commentary Bullish analysts frame the FDA decision on tasimelteon for jet lag as a limited setback rather than a thesis changer for Vanda Pharmaceuticals.
Aggiornamento della narrazione • Jan 19

VNDA: Imsidolimab Filing And Motion Sickness Approval Will Shape Balanced Outlook

Analysts have kept their fair value estimate for Vanda Pharmaceuticals steady at US$7.50, while modestly updating assumptions for the discount rate, revenue growth, profit margin, and future P/E after viewing the recent tasimelteon sNDA setback as a limited issue that was not central to their prior price target work. Analyst Commentary Street research commentary around Vanda Pharmaceuticals has framed the recent tasimelteon update as a limited issue for the equity story, with some firms explicitly stating that their valuation work did not depend on jet lag revenues for HETLIOZ.
Aggiornamento della narrazione • Jan 04

VNDA: Imsidolimab Milestones And Motion Sickness Launch Will Drive Balanced Outlook

Analysts have modestly raised their fair value estimate for Vanda Pharmaceuticals to approximately $7.50 from about $5.00 per share, citing improving milestone visibility tied to the anticipated imsidolimab BLA submission and a reassessment of long term earnings potential, even as revenue growth assumptions have become more tempered. Analyst Commentary Bearish analysts acknowledge that the clearer path toward an imsidolimab BLA filing has improved Vanda's long term earnings visibility, but they remain wary that the ultimate revenue contribution could fall short of current expectations.
User avatar
Nuova narrazione • Apr 24

New Indications And Pipeline Advances Will Strengthen Position

Expansion of Fanapt's sales and marketing efforts is expected to drive significant revenue growth through increased brand awareness and prescriber engagement.
Seeking Alpha • Sep 05

Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids

Summary Fanapt, approved for bipolar I disorder, faces significant competition from generics like Abilify, making it unlikely to drive substantial revenue growth. Ponvory, acquired from Janssen, faces similar competitive pressures, with generic versions of similar drugs dominating the multiple sclerosis market. Despite failing its primary endpoint in gastroparesis, Vanda is still pushing for regulatory approval for tradipitant, facing regulatory hurdles. Despite receiving two acquisition offers with a premium, Vanda rejected them, raising concerns about their cash management and future stock performance. Vanda's stock remains a hold due to cash strength, but limited product pipeline differentiation makes long-term growth prospects challenging. Read the full article on Seeking Alpha
Seeking Alpha • Aug 08

Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over

Summary Vanda Pharmaceuticals Inc. received and then refused two takeover bids that were well above current market prices. Vanda currently trades below net cash despite having significant revenue and operations. Vanda has disgruntled shareholders who may find creative ways to maximize shareholder value, despite a recent AGM failing to oust the unpopular Board of Directors and an existing poison pill. Retail shareholders can buy Vanda for less than the company's cash value, getting the potential benefit from the actions of activist shareholders for free. Read the full article on Seeking Alpha
Seeking Alpha • Jun 18

Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest

Summary Vanda Pharmaceuticals’ portfolio includes FDA-approved Hetlioz for sleep disorders, Fanapt for schizophrenia and bipolar I disorder, and Ponvory for multiple sclerosis. VNDA’s upcoming pipeline features milsaperidone and tradipitant, with promising Phase III trials for new indications and long-acting injectables. Acquisition offers from Future Pak and Cycle Pharmaceuticals highlight VNDA’s undervaluation and strategic value. VNDA trades below its cash value, with significant cash reserves and no debt, suggesting financial stability and growth potential. VNDA's diversified late-stage IP and substantial TAM make it a compelling investment despite the biotech and M&A risks. Read the full article on Seeking Alpha
Seeking Alpha • Apr 05

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much

Summary Vanda Pharmaceuticals Inc. stock is down 17% since my July "hold" rating; the FDA approved Fanapt for bipolar I disorder, and stock jumped. The approval of Fanapt for bipolar disorder may not significantly contribute to Vanda's bottom line as there are already several drugs approved for this indication. Despite a strong balance sheet, Vanda's future is heavily reliant on expanding existing drugs indications and new drug successes. Maintain "Hold" recommendation: Fanapt's bipolar indication is unlikely to significantly impact revenue; the company faces moderate-to-high risk. Read the full article on Seeking Alpha
Articolo di analisi • Feb 15

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

The market rallied behind Vanda Pharmaceuticals Inc.'s ( NASDAQ:VNDA ) stock, leading do a rise in the share price...
Seeking Alpha • Feb 13

Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash

Summary Vanda Pharmaceuticals is trading materially below its holdings of cash and marketable securities (worth almost $7/share). Multiple FDA approvals, if forthcoming, in 2024 could prove to be material catalysts, perhaps highlighting that the company has operational assets beyond its cash. The market's current valuation of VNDA appears too pessimistic and a range of $5-10/share may be more reasonable, even assuming imperfect capital allocation. There could be further upside if drug approvals and operational performance go well in 2024. If things trend poorly, a valuation below $4/share is possible if operational performance is weak in 2024 and FDA approvals are not forthcoming. Read the full article on Seeking Alpha
Articolo di analisi • Feb 10

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

Vanda Pharmaceuticals Inc.'s ( NASDAQ:VNDA ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a strong...
Articolo di analisi • Nov 11

News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

One thing we could say about the covering analyst on Vanda Pharmaceuticals Inc. ( NASDAQ:VNDA ) - they aren't...

Previsioni di crescita degli utili e dei ricavi

NasdaqGM:VNDA - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/2028432-45-18254
12/31/2027356-62-65-445
12/31/2026263-140-148-1425
3/31/2026218-240-137-127N/A
12/31/2025216-220-110-109N/A
9/30/2025212-84-83-82N/A
6/30/2025203-67-66-65N/A
3/31/2025201-44-59-56N/A
12/31/2024199-19-20-16N/A
9/30/2024191-16-123-18N/A
6/30/2024182-11-110-5N/A
3/31/2024178-5-115-11N/A
12/31/20231933-8813N/A
9/30/2023212122626N/A
6/30/2023238154041N/A
3/31/2023257165960N/A
12/31/202225463132N/A
9/30/202225864949N/A
6/30/2022263114546N/A
3/31/2022266185959N/A
12/31/2021269336464N/A
9/30/2021268345657N/A
6/30/2021259325557N/A
3/31/2021253326062N/A
12/31/2020248235052N/A
9/30/2020241194142N/A
6/30/20202411143839N/A
3/31/20202371173435N/A
12/31/2019227116N/A46N/A
9/30/2019219122N/A51N/A
6/30/201920928N/A54N/A
3/31/201919722N/A38N/A
12/31/201819325N/A30N/A
9/30/201818413N/A18N/A
6/30/20181771N/A12N/A
3/31/2018171-5N/A5N/A
12/31/2017165-16N/A-2N/A
9/30/2017159-14N/A-7N/A
6/30/2017156-10N/A-8N/A
3/31/2017150-13N/A-9N/A
12/31/2016146-18N/A-8N/A
9/30/2016140-32N/A-7N/A
6/30/2016129-41N/A-13N/A
3/31/2016121-42N/A2N/A
12/31/2015110-40N/A12N/A
9/30/20159345N/A-1N/A
6/30/20158053N/A-3N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che VNDA rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che VNDA rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che VNDA rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di VNDA ( 20.4% all'anno) crescerà più rapidamente del mercato US ( 11.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di VNDA ( 20.4% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di VNDA è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/25 23:04
Prezzo dell'azione a fine giornata2026/05/22 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Vanda Pharmaceuticals Inc. è coperta da 18 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
null nullArgus Research Company
Olivia BrayerBofA Global Research
Madison Wynne El-SaadiB. Riley Securities, Inc.